The National Health Surveillance Agency (Anvisa) has announced a new measure that requires the retention of medical revenue for the sale of weight loss pens such as Ozepic. The decision aims to improve control of access to these drugs, in response to the increase of adverse events related to use outside the approved indications.
Endocrinologist Fabio Trujillo, president of the Brazilian Association of Obesity Studies (ABESO), evaluates the measure as necessary. “Ozepic, whose principle is semaglutado, was being used in an abusive and indiscriminate way,” says Trujillo. He emphasizes the difference between treating obesity and using the medicine only for aesthetic weight loss.
Impacts on the treatment of chronic diseases
Trujillo expresses concern about how the new requirement may affect the continuous treatment of patients with chronic diseases such as diabetes and obesity. “My biggest concern is the patient’s access to the doctor for this renewal renewal, and how the control will be done,” he ponders.
The expert suggests that a validity of up to 90 days for revenue could be more appropriate, avoiding difficulties in accessing treatment. The ANVISA measure should take effect in mid -July, 60 days after publication in the Federal Official Gazette.
Fighting to the Parallel Market
Anvisa’s decision also aims to combat the parallel market and the irregular manipulation of these medicines. Trujillo warns of the risks associated with dubious products: “We are seeing smuggling, people being trapped at corners with pens. When we talk about manipulation, it is important to think: What is the origin? Do we have the true medication that studies show the benefits?”
The endocrinologist emphasizes the importance of treating obesity as a chronic disease, highlighting the benefits of these medications not only for weight loss, but also for the control of diabetes, blood pressure and night apnea. He concludes that combating indiscriminate use and illegal trade is critical to ensuring the safety and effectiveness of treatment.
This content was originally published in Ozepic retention retention and similar is required, says doctor on CNN Brazil.
Source: CNN Brasil
I am an experienced journalist and writer with a career in the news industry. My focus is on covering Top News stories for World Stock Market, where I provide comprehensive analysis and commentary on markets around the world. I have expertise in writing both long-form articles and shorter pieces that deliver timely, relevant updates to readers.
